Dear LabPulse reader,
This week, as 2024 comes to a close, we offer a review of the top 10 most-read LabPulse stories of the year along with the most-read stories of the week.
A biomarker and tissue imaging study exploring the effects of glucagonlike peptide-1 (GLP-1) drugs was our most popular article in 2024. A story that garnered the next largest share of our readers’ attention arrived near the end of the year and covered a VA pilot program offering no-cost pharmacogenomic (PGx) testing and PGx patient education to veterans.
Some of this year's other biggest stories include a COVID-19 test recall, a novel method for reading blood oxygen levels using a smartphone, and a report about $2.75 billion worth of lab-testing fraud, as well as other troubling money matters with payers and the rising popularity of Z-codes.
This week, our most-read stories include news of Labcorp’s latest in a series of acquisitions: select assets of Lenexa, KS-based MAWD Pathology Group's clinical and women's health testing businesses.
A report on new research from NYU’s Tandon School of Engineering using multiplex pathogen-sensing nanodevices that can be adapted to function as biosensors to detect specific pathogens or biomarkers in real time caught our readers’ attention as well.
Next, a follow-up to Novo Holdings’ acquisition of Catalent for $16.5 billion emerged as an important story for LabPulse readers. The firms announced that their merger had received no challenges from the FTC, just as with the European Commission.
Meanwhile, Roche has announced that it has received the CE Mark for its Cobas Mass Spec system, including the i601 analyzer and Ionify reagent pack of four assays for steroid hormones. The firm has also received the CE Mark for its Cobas systems update.
Rounding out our most-read articles of the week, Becton Dickson and Babson Diagnostics announced the expansion of their Texas-based pilot fingertip blood testing program, which uses a collaboratively developed collection kit designed to make blood testing more accessible and simpler.
This will be the last newsletter of 2024, as we won’t be sending newsletters during the upcoming holiday season. We’ll return January 2. We wish you a happy holiday season; see you in 2025.
Thanks for reading.
